Cargando…
Cost-effectiveness of dronedarone and standard of care compared with standard of care alone: US results of an ATHENA lifetime model
BACKGROUND: The first antiarrhythmic drug to demonstrate a reduced rate of cardiovascular hospitalization in atrial fibrillation/flutter (AF/AFL) patients was dronedarone in a placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of...
Autores principales: | Reynolds, Matthew R, Nilsson, Jonas, Åkerborg, Örjan, Jhaveri, Mehul, Lindgren, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544268/ https://www.ncbi.nlm.nih.gov/pubmed/23326201 http://dx.doi.org/10.2147/CEOR.S36019 |
Ejemplares similares
-
Dronedarone in patients with congestive heart failure: insights from ATHENA
por: Hohnloser, Stefan H., et al.
Publicado: (2010) -
Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study
por: Torp-Pedersen, Christian, et al.
Publicado: (2011) -
Efficacy and safety of dronedarone by atrial fibrillation history duration: Insights from the ATHENA study
por: Blomström‐Lundqvist, Carina, et al.
Publicado: (2020) -
Impact of Dronedarone Treatment on Healthcare Resource Utilization in Patients with Atrial Fibrillation/Flutter
por: Kim, Michael H., et al.
Publicado: (2014) -
Efficacy and safety of dronedarone in patients with a prior ablation for atrial fibrillation/flutter: Insights from the ATHENA study
por: Vamos, Mate, et al.
Publicado: (2019)